Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NordCML006: Dasatinib vs Imatinib in Newly Diagnosed CP CML
NCT00852566Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Mar 2009
- Primary completion
- Feb 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Norwegian University of Science and Technology. Started Mar 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00852566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00852566.